Everything that you should know about the multiple myeloma treatment Melflufen and the results of the phase 2 HORIZON clinical trial.
Everything that you should know about Inovio (NASDAQ: INO) receiving $5 million from Bill and Melinda Gates for its COVID-19 vaccine program.
Clinical Trial Demonstrates Enhancement of Immune Response to HIV by Gilead’s TLR7 Agonist Vesatolimod
Gilead (Nasdaq: GILD) has announced clinical trial results demonstrating the enhancement of the immune response to HIV by the TLR7 agonist Vesatolimod.
NuVasive, Inc. (Nasdaq: NUVA) has announced a recent publication demonstrating the efficacy of their synthetic bioactive putty in lumbar fusion.
Timeline and latest updates regarding phase 3 trials of the antiviral agent remdesivir for the treatment of COVID-19 initiated by Gilead.
Novel engineered nanoparticles have the ability to selectively deliver immune checkpoint blockade (ICB) therapy to tumors, allowing for targeted immunotherapy that is more efficient and has reduced side effects.
A novel Ebola vaccine demonstrates highly effective immunization against the virus, completely protecting all tested patients from infection, and is stable for long periods at refrigerator temperatures, marking a new milestone in the battle against this deadly disease.